Embio is an API manufacturer based in India. It holds 3 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 2 May 2025 as NAI. Customs aggregates show $56.7M of exports covering 725 molecules to 57 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Mahad, India | 1000283831 |
| Molecule | Regulators | Docs |
|---|---|---|
| Pseudoephedrine | SFDA (Saudi Arabia), US FDA | 3 |
| Ephedrine | SFDA (Saudi Arabia), US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $5.2M | 28 |
| 2025 | Not reported | $56.7M | 57 |
| 2024 | Not reported | $21.2M | 57 |
| 2023 | Not reported | $18.3M | 57 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Embio comes back tiered against every other supplier able to file there.
Start for free